Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer

被引：0

作者：

Chang, M. ^{[1
]}

Mccormick, C. ^{[1
]}

Kwok, B. ^{[2
]}

Li, Y. ^{[3
]}

Kyeremateng, Y. ^{[1
]}

Aktas, A. ^{[4
]}

Singh, R. ^{[1
]}

Singh, S. ^{[5
]}

Li, Q. ^{[6
]}

Kugler, M. C. ^{[7
]}

Pass, H. ^{[8
]}

Sterman, D. H. ^{[9
]}

Wu, B. G. ^{[10
]}

Segal, L. N. ^{[3
]}

Tsay, J. J. ^{[11
]}

机构：

[1] NYU Langone Hlth, New York, NY USA

[2] NYU, New York, NY USA

[3] NYU, Sch Med, Med, New York, NY USA

[4] Vet Affairs New York Harbor Healthcare Syst, Med, New York, NY USA

[5] NYU, Sch Med, Pulm & Crit Care Med, New York, NY USA

[6] NYU, Sch Med, Div Pulm & Crit Care Med, New York, NY USA

[7] New York Univ Hosp Ctr, Med, New York, NY USA

[8] NYU Langone Hlth, Bronxville, NY USA

[9] NYU, Sch Med, NYU Langone Med Ctr, New York, NY USA

[10] Dept Internal Med, Div Pulm Crit Care & Sleep Med, New York, NY USA

[11] NYU, Sch Med, Pulm Crit Care, New York, NY USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A6691

引用

页数：2

共 50 条

[21] High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models
Kim, Hak Su
Kwon, Seung-hyun
Choi, Ok Kyung
Lim, Taekyu
FRONTIERS IN IMMUNOLOGY, 2025, 15
[22] Comparison of iRECIST to RECIST1.1 for Following Response to Anti-PD1 Therapy in Patients with Non-Small Cell Lung Cancer (NSCLC)
Katz, S.
Hammer, M.
Bagley, S.
Aggarwal, C.
Bauml, J.
Nachiappan, A.
Simone, C.
Langer, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1551 - S1551
[23] Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy
Duma, N.
Azzouqa, A-G.
Yadav, S.
Hoversten, K.
Reed, C.
Sitek, A. N.
Lou, Y.
Molina, J.
Halfdanarson, T.
Leventakos, K.
Joseph, R. W.
Manochakian, R.
Dronca, R.
ANNALS OF ONCOLOGY, 2018, 29 : 432 - 432
[24] MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
Lecuelle, Julie
Favier, Laure
Fraisse, Clea
Lagrange, Aurelie
Kaderbhai, Coureche
Boidot, Romain
Chevrier, Sandy
Joubert, Philippe
Routy, Bertrand
Truntzer, Caroline
Ghiringhelli, Francois
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
[25] A single centre experience of anti-PDL1 and anti-PD1 agents in treatment of non-small cell lung cancer (NSCLC)
Saunders, E.
Rubasingham, J.
Muthukumar, D.
Ingle, C.
LUNG CANCER, 2019, 127 : S44 - S44
[26] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, Chaoyue
Wang, Hui
Liu, Yunru
Guo, Qiaoru
Zhang, Lingling
Li, Jiajun
Zhou, Wenmin
Yan, Yanyan
Zhou, Xinke
Zhang, Jianye
FRONTIERS IN ONCOLOGY, 2020, 10
[27] INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
Yam, A. O.
Mersiadis, A.
Gao, B.
Hui, R.
Nagrial, A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 72
[28] Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer
Zhao, Lianqi
Li, Tingting
Zhou, Yinwei
Wang, Pengbo
Luo, Lin
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
[29] Alterations of lung microbiota in patients with non-small cell lung cancer
Zeng, Wen
Zhao, ChengZhu
Yu, Mengge
Chen, Hailong
Pan, Yiyun
Wang, Yuhuan
Bao, Hejing
Ma, Hao
Ma, Shudong
BIOENGINEERED, 2022, 13 (03) : 6665 - 6677
[30] Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Katz, Sharyn I.
Hammer, Mark
Bagley, Stephen J.
Aggarwal, Charu
Bauml, Joshua M.
Thompson, Jeffrey C.
Nachiappan, Arun C.
Simone, Charles B., II
Langer, Corey J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 978 - 986

← 1 2 3 4 5 →